Primary Hyperoxaluria Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies Involved by DelveInsight | Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Primary Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Primary Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Primary Hyperoxaluria Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.


Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report:

Companies across the globe are diligently working toward developing novel Primary Hyperoxaluria treatment therapies with a considerable amount of success over the years. 
Primary Hyperoxaluria companies working in the treatment market are Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Primary Hyperoxaluria treatment 

Emerging Primary Hyperoxaluria therapies in the different phases of clinical trials are- CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.   
In September 2022, Nedosiran was submitted for regulatory approval to the US FDA by Novo Nordisk.
In February 2022, In order to assess the safety, pharmacokinetics, and efficacy of Nedosiran in paediatric patients from birth to 11 years of age with primary hyperoxaluria and reasonably intact renal function, Dicerna Pharmaceuticals, Inc. started a Phase II open-label multicenterstudy.


Primary Hyperoxaluria Overview

A series of rare inherited metabolic illnesses known as Primary Hyperoxaluria (PH) are characterized by the buildup of the chemical oxalate in the kidneys and other organ systems of the body. A particular enzyme that typically inhibits the accumulation of oxalate is absent from affected people.


Get a Free Sample PDF Report to know more about Primary Hyperoxaluria Pipeline Therapeutic Assessment-


Emerging Primary Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:

CHK-336: Chinook Therapeutics
BBP-711: Cantero Therapeutics
BMN 255: BioMarin Pharmaceutical, Inc
Oxabact: OxThera
Nedosiran: Dicerna Pharmaceuticals, Inc.


Primary Hyperoxaluria Route of Administration

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 



Primary Hyperoxaluria Molecule Type

Primary Hyperoxaluria Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Small molecule
Gene therapy 


Primary Hyperoxaluria Pipeline Therapeutics Assessment

Primary Hyperoxaluria Assessment by Product Type
Primary Hyperoxaluria By Stage and Product Type
Primary Hyperoxaluria Assessment by Route of Administration
Primary Hyperoxaluria By Stage and Route of Administration
Primary Hyperoxaluria Assessment by Molecule Type
Primary Hyperoxaluria by Stage and Molecule Type


DelveInsight’s Primary Hyperoxaluria Report covers around 8+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration


Further Primary Hyperoxaluria product details are provided in the report. Download the Primary Hyperoxaluria pipeline report to learn more about the emerging Primary Hyperoxaluria therapies


Some of the key companies in the Primary Hyperoxaluria Therapeutics Market include:

Key companies developing therapies for Primary Hyperoxaluria are – Oxthera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, among others


Primary Hyperoxaluria Pipeline Analysis:

The Primary Hyperoxaluria pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxaluria with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria Treatment.
Primary Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Primary Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxaluria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Primary Hyperoxaluria drugs and therapies


Primary Hyperoxaluria Pipeline Market Drivers

Rising Prevalence of Primary hyperoxaluria, increasing demand of disease specific novel treatments are some of the important factors that are fueling the Primary Hyperoxaluria Market.


Primary Hyperoxaluria Pipeline Market Barriers

However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Primary Hyperoxaluria Market growth.


Scope of Primary Hyperoxaluria Pipeline Drug Insight    

Coverage: Global
Key Primary Hyperoxaluria Companies: Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others
Key Primary Hyperoxaluria Therapies: CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others
Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers 


Request for Sample PDF Report for Primary Hyperoxaluria Pipeline Assessment and clinical trials


Table of Contents 

1. Primary Hyperoxaluria Report Introduction

2. Primary Hyperoxaluria Executive Summary

3. Primary Hyperoxaluria Overview

4. Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment

5. Primary Hyperoxaluria Pipeline Therapeutics

6. Primary Hyperoxaluria Late Stage Products (Phase II/III)

7. Primary Hyperoxaluria Mid Stage Products (Phase II)

8. Primary Hyperoxaluria Early Stage Products (Phase I)

9. Primary Hyperoxaluria Preclinical Stage Products

10. Primary Hyperoxaluria Therapeutics Assessment

11. Primary Hyperoxaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Hyperoxaluria Key Companies

14. Primary Hyperoxaluria Key Products

15. Primary Hyperoxaluria Unmet Needs

16 . Primary Hyperoxaluria Market Drivers and Barriers

17. Primary Hyperoxaluria Future Perspectives and Conclusion

18. Primary Hyperoxaluria Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: